{'output': [['Allergan Plc', 'COMP', 'See', '2018 GAAP Net Revenue', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'See', '2018 GAAP Performance Loss Per Share', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'See', '2018 Non-GAAP Performance Earnings Per Share', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'Plan', 'Sell Remaining Position in Teva', 'COMP'], ['Allergan Plc', 'COMP', 'Has', 'Prudently Divest', 'SECTOR', 'Relate_To', 'Securities of Teva', 'COMP'], ['Allergan Plc', 'COMP', 'Anticipates', 'Future Impact of Tax Cut and Jobs Act', 'CONCEPT', 'Impact_On', 'CO‘s Non-GAAP Effective Tax Rate', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'Sees', 'No Generic Entry for Restasis Prior to Q2 2018', 'EVENT'], ['Allergan Plc', 'COMP', 'Sees', 'Ongoing Cost Reductions of $300 Million – $400 Million in 2018', 'ECON_INDICATOR', 'From', 'Fiscal 2017 Non-GAAP Operating Expenses', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'Faces', 'Loss of Exclusivity Revenue Headwinds in 2018', 'CONCEPT']]}